Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Reversible MAO inhibitors from Hoechst Marion Roussel

Sep. 6, 1996

Lilly's olanzapine deemed approvable

Sep. 6, 1996

Antipsychotic dopaminergic compounds from E. Merck

Sep. 6, 1996

Lilly discloses new serotonergic agents

Sep. 6, 1996

NS-2710 in development for anxiety

Sep. 6, 1996

Melatonergic agents from ADIR

Sep. 6, 1996

BTG licenses analgesic combination to Forest

Sep. 6, 1996

FDA approves two pain products from Mallinckrodt

Sep. 6, 1996

NPC-18521, a high-affinity bradykinin B2 receptor antagonist from Scios

Sep. 6, 1996

New introductions for Faulding's sustained-release morphine product

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...